Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560


Company Overview

Corporate Profile
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 2.98 (3.25%)
Data as of 11/21/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
11/11/14Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2014 Global London Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 11, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2014 Global London Healthcare Conference at 10:40 a.m. GMT (5:40 a.m. ET) on Wednesday, Nov. 19, 2014, in London. Mr. Stack is expected to present an overview of the company. A live audio webc... 
Printer Friendly Version
11/06/14Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain Following Total Knee Arthroplasty
-- Data Presented at the 2014 Annual Meeting of the American Association of Hip and Knee Surgeons Finds Lower Patient-Perceived Pain Scores, Reduced Opioid Consumption and Improved Patient Satisfaction in Patients Who Received EXPAREL – PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 6, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study designed to evaluate the difference in p... 
Printer Friendly Version
10/30/14Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 30, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2014. “The third quarter marked another period of consisten... 
Printer Friendly Version
10/27/14New Study Correlates Use of EXPAREL for Postsurgical Pain Management with Significant Reductions in Opioid Related Adverse Events
--Data from American College of Surgeons Demonstrates Reduced Incidence of Respiratory Depression, Urinary Retention and Fall Risk in Patients Receiving EXPAREL-- PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 27, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study that reinforce the positive impact of an EXPAREL-based pain management regimen on reducing postsurgical complicat... 
Printer Friendly Version

Corporate Presentation

Corporate Presentation
Upcoming EventsMore >>
Brean Capital 2014 Life Science Summit
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Contact Investor Relations:
Jessica Cho
(973) 254-3574